Are endometrial mesenchymal stem cells a better efficacious and safer blood-compatible MSC source?

Research area

 |  Endometriosis


 |  endometrila MSC, clotting, haemocompatibility, clinical application


 |  PhD/Doctorate, Honours

Contact supervisors at any time

Dr Shanti Gurung

Project description

Global Market Insights estimates the mesenchymal stem cells (MSCs) market size to grow from USD 3 billion in 2022 to USD 10.3 billion by 2032 due to the rising prevalence of chronic diseases. As of 2023, more than 1500 MSCs-based clinical trials have been registered in Almost half of the application is delivered intravascularly.

This project looks to

  1. Characterise the haemocompatibility profile of endometrial-derived MSC and
  2. Determine if they are compatible with human whole blood for intravascular mode of administration.

This project utilises cell culture and in-vitro disease models of infection and inflammation (key culprits to most diseases) and assesses whether endometrial MSCs are safe to treat diseases through intravascular mode. Techniques: Stem cell isolation, sterile cell culture, flow cytometry, Western Blotting, RT-PCR, quantitative and qualitative measurement of clotting elasticity.